Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma

This trial is testing a combination of spartalizumab (an immunotherapy drug), chemotherapy (mDCF: modified docetaxel, cisplatin, and fluorouracil), and radiation therapy in patients with metastatic or locally advanced recurring squamous cell cancer of the anus. **You may be eligible if...** - You are 18 or older with a confirmed metastatic or locally recurrent squamous cell carcinoma of the anus - You have good performance status (ECOG ≤1) - You have measurable disease on imaging - You are eligible for the chemotherapy regimen used in this trial (mDCF) - You have adequate organ function - You are affiliated with the French social security system **You may NOT be eligible if...** - You are HIV-positive with a low CD4 count (below 400 cells/mm³) - You have another active cancer (diagnosed within 2 years, with limited exceptions) - You have received anti-cancer treatment in the past 4 weeks - You are pregnant or breastfeeding - You have active autoimmune disease, active serious infections, or inflammatory bowel disease - You have significant heart disease or neuropathy that prevents cisplatin use - You have active hepatitis B or C Talk to your doctor to see if this trial is right for you.